Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Trans-Activator Of Transcription (Tat) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Trans-Activator Of Transcription (Tat) Products under Development by Stage of Development | 7 | 1 |
| Trans-Activator Of Transcription (Tat) Products under Development by Therapy Area | 8 | 1 |
| Trans-Activator Of Transcription (Tat) Products under Development by Indication | 9 | 1 |
| Trans-Activator Of Transcription (Tat) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Trans-Activator Of Transcription (Tat) Products under Development by Companies | 12 | 2 |
| Trans-Activator Of Transcription (Tat) Products under Development by Universities/Institutes | 14 | 2 |
| Trans-Activator Of Transcription (Tat) Therapeutics Assessment | 16 | 6 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 2 |
| Trans-Activator Of Transcription (Tat) Companies Involved in Therapeutics Development | 22 | 2 |
| Akshaya Bio Inc. | 22 | 1 |
| Biosantech SA | 23 | 1 |
| Trans-Activator Of Transcription (Tat) Drug Profiles | 24 | 9 |
| CSTATI-1 Drug Profile | 24 | 2 |
| HIV vaccine Drug Profile | 26 | 2 |
| HIV vaccine Drug Profile | 28 | 1 |
| HIV vaccine Drug Profile | 29 | 1 |
| HIV-1 vaccine Drug Profile | 30 | 2 |
| Recombinant Protein to Inhibit Tat and Rev for HIV-1 Drug Profile | 32 | 1 |
| Trans-Activator Of Transcription (Tat) Dormant Projects | 33 | 1 |
| Trans-Activator Of Transcription (Tat) Discontinued Products | 34 | 1 |
| Trans-Activator Of Transcription (Tat) Featured News &Press Releases | 35 | 7 |
| Jun 08, 2016: Improving the Effect of HIV Drugs by Use of the Tat Vaccine | 35 | 1 |
| Mar 15, 2016: Publication in Retrovirology of the results of Biosantech's phase IIA clinical trial for the anti-HIV candidate vaccine | 36 | 1 |
| Jul 29, 2015: Cannabis Science Signs Gary Blick, MD and Proceeds With CS-TATI-1 for HIV and Kaposi Sarcoma Drug Development Program | 36 | 1 |
| Jan 02, 2015: HIV vaccines should avoid viral target cells, primate model study suggests | 37 | 1 |
| Apr 26, 2013: Cannabis Science Announces Preclinical Development Program For CS-TATI-I | 38 | 1 |
| Nov 12, 2012: Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Science's Approach To Development Of CS-TATI-1 To Inhibit Kaposi Sarcoma | 39 | 1 |
| Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi s Sarcoma | 40 | 1 |
| Aug 13, 2012: CBIS Initiates GMP Development Plan For CS-TATI-1 | 41 | 1 |
| Appendix | 42 | 2 |
| Methodology | 42 | 1 |
| Coverage | 42 | 1 |
| Secondary Research | 42 | 1 |
| Primary Research | 42 | 1 |
| Expert Panel Validation | 42 | 1 |
| Contact Us | 42 | 1 |
| Disclaimer | 43 | 1 |